Efficacy and safety of propranolol for epistaxis in hereditary haemorrhagic telangiectasia: retrospective, then prospective study, in a total of 21 patients

Clin Otolaryngol. 2017 Aug;42(4):911-917. doi: 10.1111/coa.12821. Epub 2017 Jan 20.

Authors

A Contis¹, N Gensous¹, J F Viallard², C Goizet³, C Léauté-Labrèze⁴, P Duffau¹

Affiliations

¹ Service de médecine interne et immunologie clinique, Hôpital Saint André, Bordeaux, France.
² Service de médecine interne, Hôpital Haut- Lévêque, Pessac, France.
³ Service de génétique médicale, Hôpital Pellegrin, Bordeaux, France.
⁴ Service de dermatologie pédiatrique et Centre de référence maladies rares de la peau, Hôpital Pellegrin, Bordeaux, France.

PMID: 28032956
DOI: 10.1111/coa.12821

No abstract available

MeSH terms

Adrenergic beta-Antagonists / therapeutic use*
Adult
Aged
Epistaxis / drug therapy*
Epistaxis / etiology
Female
Humans
Male
Middle Aged
Propranolol / therapeutic use*
Prospective Studies
Retrospective Studies
Telangiectasia, Hereditary Hemorrhagic / complications*
Treatment Outcome

Substances

Adrenergic beta-Antagonists
Propranolol